background
pulmonari
exacerb
pex
children
cystic
fibrosi
cf
frequent
treat
outpati
set
oral
antibiot
howev
littl
known
characterist
pex
manag
outpati
basi
effect
oral
antibiot
therapi
sought
prospect
evalu
clinic
laboratori
chang
associ
oral
antibiot
treatment
pex
method
children
cf
year
age
prescrib
two
week
oral
antibiot
pex
elig
enrol
studi
consist
visit
within
h
start
antibiot
second
visit
within
one
week
antibiot
complet
twentyeight
particip
evalu
exacerb
score
qualiti
life
measur
lung
function
sputum
microbiolog
inflamm
result
oral
antibiot
treatment
associ
signific
improv
exacerb
score
qualiti
life
measur
cf
questionnairerevis
cfqr
respiratori
domain
follow
treatment
forc
expiratori
volum
fev
predict
increas
median
rang
subject
return
higher
baselin
fev
bacteri
densiti
primari
organ
identifi
sputum
cultur
decreas
significantli
median
rang
decreas
log
cfuml
log
log
p
sputum
neutrophil
elastas
p
p
decreas
significantli
follow
treatment
cohort
conclus
treatment
pex
oral
antibiot
associ
measur
improv
patient
report
outcom
lung
function
bacteri
densiti
sputum
inflammatori
marker
publish
elsevi
bv
behalf
european
cystic
fibrosi
societi
pulmonari
exacerb
pex
frequent
occurr
cystic
fibrosi
cf
character
constel
symptom
includ
increas
cough
increas
sputum
product
decreas
exercis
toler
pex
frequent
treat
outpati
set
oral
antibiot
especi
younger
patient
preserv
lung
function
howev
despit
routin
use
oral
antibiot
treat
symptom
pex
limit
data
avail
describ
clinic
laboratori
chang
occur
onset
pex
subsequ
oral
antibiot
treatment
multipl
studi
examin
clinic
outcom
intraven
iv
antibiot
treatment
pex
perform
howev
result
studi
may
generaliz
pex
treat
oral
antibiot
key
gap
knowledg
relat
oral
antibiot
treatment
pex
pediatr
patient
cf
includ
chang
clinic
outcom
recoveri
lung
function
alter
bacteri
densiti
measur
airway
inflamm
therefor
sought
prospect
determin
chang
patient
report
outcom
lung
function
airway
infect
inflamm
cohort
school
age
children
cf
treat
pex
oral
antibiot
outpati
set
subject
age
year
diagnosi
cf
base
sweat
chlorid
meql
andor
presenc
two
known
cftr
mutat
met
criteria
pex
prescrib
oral
antibiot
treatment
elig
enrol
individu
met
criteria
pulmonari
exacerb
score
higher
possibl
point
base
symptom
prior
two
week
physic
exam
find
score
base
assess
follow
worsen
cough
sputum
product
chest
tight
exercis
toler
miss
school
work
new
auscultatori
find
chest
exam
subject
exclud
particip
fev
predict
receiv
chronic
oral
antibiot
receiv
oral
iv
antibiot
within
prior
two
week
simultan
start
inhal
antibiot
receiv
inhal
antibiot
part
chronic
manag
elig
enrol
inhal
antibiot
continu
previous
schedul
receiv
chronic
thrice
weekli
azithromycin
also
elig
enrol
subject
elig
particip
studi
could
reenrol
second
exacerb
subject
recruit
either
cf
clinic
time
antibiot
prescript
phone
subject
primari
cf
provid
prescrib
antibiot
base
telephon
triag
studi
consist
visit
within
h
start
antibiot
second
visit
within
one
week
antibiot
complet
patient
receiv
twoweek
cours
oral
antibiot
antibiot
choic
determin
primari
cf
provid
use
cf
center
standard
approach
antibiot
select
base
prior
respiratori
cultur
result
demograph
inform
includ
age
gender
race
medic
histori
genotyp
cf
comorbid
medic
record
pulmonari
function
test
perform
preand
postbronchodil
research
visit
baselin
lung
function
measur
defin
highest
fev
valu
prior
six
month
compar
prebronchodil
valu
pex
onset
end
antibiot
result
pulmonari
function
test
month
follow
exacerb
also
captur
highest
fev
time
frame
compar
postantibiot
valu
sputum
sampl
either
expector
induc
obtain
assess
infect
inflamm
see
next
section
detail
viral
test
sputum
multiplex
polymeras
chain
reaction
pcr
panel
virus
perform
first
visit
see
next
section
addit
detail
pulmonari
exacerb
score
pe
obtain
visit
qualiti
life
measur
assess
use
cf
questionnairerevis
colorado
multipl
institut
review
board
approv
studi
inform
consent
assent
appropri
obtain
patient
hipaa
standard
maintain
studi
two
sputum
sampl
visit
collect
patient
subject
unabl
expector
sputum
induct
perform
dedic
clinic
room
accord
standard
oper
procedur
previous
publish
one
sampl
sent
clinic
microbiolog
lab
process
underw
comprehens
examin
cf
bacteri
fungal
pathogen
per
cf
consensu
guidelin
addit
sputum
sampl
test
virus
use
respiratori
viru
pcr
luminex
molecular
diagnost
xtag
rvp
assay
detect
follow
virus
influenza
ab
human
metapneumoviru
respiratori
syncyti
viru
parainfluenza
adenoviru
coronaviru
rhinovirusenteroviru
second
sampl
sent
pediatr
clinic
translat
research
center
core
laboratori
children
hospit
colorado
process
use
standard
oper
procedur
cytolog
includ
total
cell
count
neutrophil
measur
follow
inflammatori
marker
free
neutrophil
elastas
ne
activ
human
mobil
group
box
hmgb
interleukin
il
criteria
sputum
accept
found
onlin
supplement
sputum
cytolog
perform
subset
sampl
n
immedi
process
within
min
collect
possibl
ne
activ
quantifi
spectrophotometr
assay
base
hydrolysi
specif
substrat
meosucalaalaproalapnitroanilid
sigma
chemic
co
st
loui
mo
quantifi
luminex
multiplex
platform
use
commerci
avail
reagent
r
system
minneapoli
mn
measur
use
enzymelink
immunosorb
assay
ibl
intern
morrisvil
nc
lower
limit
detect
assay
ne
activ
pgml
pgml
ngml
studi
power
expect
reduct
bacteri
densiti
assum
bacteri
coloni
count
would
reduc
lesser
degre
oral
antibiot
iv
treatment
sampl
size
subject
mean
chang
bacteri
densiti
log
cfuml
coloni
form
unit
could
detect
power
signific
level
domin
bacteri
pathogen
defin
bacterium
isol
highest
concentr
first
sputum
cultur
use
assess
reduct
bacteri
densiti
bacteri
densiti
log
transform
prior
perform
statist
analys
sign
rank
test
use
compar
variabl
follow
two
week
antibiot
cours
lung
function
secondari
outcom
calcul
use
global
lung
initi
equat
evalu
multipl
time
point
use
repeat
measur
anova
lasso
regress
model
fit
percent
fev
recoveri
variabl
identifi
predictor
recoveri
defin
fev
within
baselin
elig
variabl
model
gender
fev
predict
start
pex
pe
age
neg
viral
pcr
neg
cf
pathogen
cultur
posit
bacteri
cultur
pseudomona
aeruginosa
mutat
sinc
percent
recoveri
drop
fev
baselin
function
valu
baselin
highli
correl
see
supplement
fig
reason
opt
includ
fev
valu
pex
onset
sinc
valu
includ
percent
recoveri
calcul
would
therefor
effect
spuriou
correl
thirtytwo
children
cf
enrol
studi
two
subject
withdrew
prior
complet
visit
one
subject
return
second
studi
visit
one
subject
withdrawn
studi
due
new
growth
p
aeruginosa
initi
inhal
antibiot
demograph
inform
clinic
characterist
subject
complet
visit
n
list
tabl
tabl
captur
baselin
prior
onset
pex
visit
data
genotyp
distribut
averag
lung
function
cohort
gener
reflect
overal
pediatr
popul
chang
clinic
laboratori
outcom
oral
antibiot
treatment
cohort
describ
tabl
twentysix
subject
complet
diari
track
time
antibiot
dose
airway
clearanc
subject
perform
mean
airway
clearanc
treatment
rang
twoweek
period
averag
airway
clearanc
treatment
per
day
twoweek
period
subject
report
miss
averag
less
one
antibiot
dose
rang
median
baselin
pulmonari
exacerb
score
pe
rang
n
median
chang
pe
follow
complet
oral
antibiot
p
b
supplement
fig
signific
improv
respiratori
domain
cfqr
observ
patient
parent
report
questionnair
supplement
fig
patient
respiratori
domain
score
median
rang
improv
p
b
postantibiot
compar
preantibiot
score
parent
report
respiratori
domain
score
median
improv
p
b
follow
antibiot
signific
chang
domain
cfqr
physic
emot
bodi
imag
eat
treatment
burden
digest
subject
enrol
studi
median
baselin
fev
predict
rang
first
visit
median
decreas
rang
fev
predict
observ
median
fev
valu
predict
rang
follow
oral
antibiot
treatment
median
increas
fev
predict
rang
p
b
fig
two
week
antibiot
subject
return
baselin
subject
return
baselin
subject
return
previou
baselin
subject
return
within
baselin
treatment
guid
primari
cf
provid
receiv
addit
two
week
oral
antibiot
hospit
receiv
treatment
addit
antibiot
cours
start
complet
visit
measur
correl
chang
respiratori
domain
cfrq
recoveri
baselin
fev
r
p
also
correl
recoveri
baselin
fev
total
number
airway
clearanc
treatment
perform
r
p
differ
chang
fev
base
length
time
visit
see
supplement
fig
among
subject
underw
preand
postbronchodil
pulmonari
function
test
five
subject
airway
hyperreact
subject
hyperreact
visit
hyperreact
visit
visit
one
subject
hyperreact
visit
postbronchodil
test
complet
visit
pulmonari
function
test
also
captur
routin
clinic
visit
month
exacerb
median
decreas
highest
fev
predict
subsequ
month
compar
fev
predict
end
exacerb
virus
detect
subject
rhinovirusenteroviru
detect
commonli
n
follow
coronaviru
n
rsv
n
one
subject
two
virus
detect
rsv
coronaviru
relationship
viral
posit
season
supplement
fig
correl
presenc
posit
viral
pcr
decreas
fev
baselin
time
exacerb
chang
lung
function
oral
antibiot
significantli
differ
infect
viru
without
viral
infect
p
cf
respiratori
cultur
result
obtain
first
studi
visit
list
tabl
methicillin
sensit
methicillin
resist
staphylococcu
aureu
mssa
mrsa
p
aeruginosa
frequent
detect
cf
pathogen
initi
sputum
cultur
pair
sputum
sampl
collect
visit
detect
pathogen
visit
obtain
subject
n
neg
visit
n
insuffici
quantiti
visit
n
insuffici
quantiti
visit
match
sampl
expector
visit
expector
initi
visit
requir
sputum
tabl
chang
clinic
laboratori
outcom
oral
antibiot
treatment
induct
follow
sputum
sampl
insuffici
sampl
visit
visit
total
sampl
failur
collect
sputum
rate
ci
median
bacteri
densiti
domin
organ
start
exacerb
log
rang
coloni
form
unit
cfuml
among
subject
decreas
bacteri
coloni
count
domin
organ
follow
antibiot
treatment
median
rang
decreas
log
cfuml
log
log
p
subject
fig
median
increas
mssa
log
cfuml
bacteri
densiti
mrsa
p
aeruginosa
decreas
log
cfuml
common
antibiot
prescrib
subject
mssa
primari
bacterium
sputum
cultur
amoxicillinclavulan
acid
n
patient
grew
mssa
sputum
cultur
treat
amoxicillinclavulan
acid
improv
fev
greater
prior
baselin
remain
subject
prior
baselin
therefor
lack
reduct
bacteri
densiti
congruent
clinic
improv
observ
subset
patient
neither
baselin
bacteri
densiti
chang
bacteri
densiti
associ
recoveri
baselin
fev
entir
cohort
differ
chang
bacteri
densiti
base
length
time
visit
see
supplement
fig
signific
decreas
sputum
ne
activ
median
rang
p
p
fig
signific
chang
observ
sputum
p
p
among
patient
pair
cytolog
assess
signific
differ
total
white
blood
cell
count
p
percent
neutrophil
p
associ
baselin
ne
chang
ne
chang
return
baselin
fev
also
correl
chang
sputum
inflammatori
marker
chang
bacteri
densiti
risk
factor
fail
return
baselin
lung
function
fev
predict
start
pex
age
associ
recoveri
baselin
fev
rsquar
final
model
variabl
posit
associ
increas
likelihood
recoveri
baselin
fev
mean
older
higher
fev
predict
start
exacerb
like
recov
within
prior
baselin
pex
common
cf
frequent
treat
oral
antibiot
outpati
set
despit
limit
evid
demonstr
effect
sever
notabl
find
prospect
studi
oral
antibiot
treatment
pex
school
age
children
cf
patient
studi
report
feel
better
follow
two
week
cours
oral
antibiot
signific
improv
seen
pe
cfqr
respiratori
domain
lung
function
significantli
improv
though
note
approxim
subject
fail
return
within
baselin
fev
valu
complet
two
week
antibiot
therapi
addit
antibiot
treatment
associ
signific
decreas
sputum
bacteri
densiti
sputum
ne
much
knowledg
cf
pex
treat
outpati
set
deriv
retrospect
studi
registrybas
studi
found
frequent
prescrib
antibiot
associ
better
lung
function
though
exacerb
treat
oral
antibiot
associ
less
improv
fev
decreas
likelihood
return
baselin
lung
function
compar
iv
treatment
singl
center
retrospect
studi
highlight
approxim
subject
fail
exacerb
treatment
oral
antibiot
requir
treatment
iv
antibiot
addit
stanojev
colleagu
evalu
drop
fev
start
exacerb
improv
fev
end
oral
antibiot
treatment
long
term
follow
within
three
month
larg
cohort
patient
cf
although
lower
proport
subject
fev
determin
end
treatment
approxim
twothird
recov
within
baselin
complet
oral
antibiot
treatment
improv
subsequ
follow
best
valu
within
three
month
also
demonstr
declin
fev
greater
frequent
exacerb
popul
studi
stanojev
colleagu
older
signific
underli
lung
diseas
base
averag
fev
compar
cohort
addit
given
retrospect
natur
studi
subset
followup
evalu
time
antibiot
complet
also
unclear
smaller
subset
may
reflect
group
remain
symptomat
thu
like
receiv
close
followup
rather
reflect
overal
popul
may
explain
return
baselin
lung
function
lower
time
point
ratjen
colleagu
perform
similarli
design
prospect
studi
examin
chang
clinic
outcom
bacteri
densiti
airway
inflamm
follow
oral
antibiot
treatment
pex
pediatr
patient
cf
report
improv
exacerb
symptom
score
fev
reduct
bacteri
densiti
similar
cohort
observ
signific
chang
sputum
inflammatori
marker
includ
ne
activ
contrast
cohort
surpris
given
patient
lower
baselin
fev
higher
sputum
bacteri
densiti
higher
sputum
compar
cohort
treat
week
rather
antibiot
studi
larger
number
subject
need
definit
determin
effect
oral
antibiot
measur
airway
inflamm
treatment
exacerb
inpati
set
iv
antibiot
extens
studi
studi
demonstr
signific
number
subject
fail
return
within
baselin
lung
function
interestingli
compar
percentag
subject
return
baselin
lung
function
cohort
inpati
treatment
benefit
may
due
part
intens
airway
clearanc
regimen
reduct
sputum
bacteri
densiti
cohort
lower
report
treat
iv
antibiot
pex
lesser
reduct
bacteri
densiti
subject
may
due
increas
efficaci
iv
antibiot
treat
bacteria
lower
airway
differ
antibiot
option
avail
iv
form
differ
spectrum
activ
iv
antibiot
compar
oral
treatment
anoth
possibl
intens
airway
clearanc
regimen
hospit
facilit
clear
bacteria
lower
airway
cohort
associ
number
airway
clearanc
treatment
perform
recoveri
baselin
import
note
chang
bacteri
densiti
may
predict
clinic
respons
observ
studi
studi
patient
receiv
iv
antibiot
target
p
aeruginosa
one
studi
also
found
viral
infect
alter
bacteri
densiti
patient
p
aeruginosa
treat
cf
pex
howev
anoth
studi
cf
exacerb
treat
iv
antibiot
detect
virus
associ
less
treatment
respons
contrast
find
viral
infect
appear
influenc
treatment
respons
possibl
reflect
sever
viral
ill
exacerb
account
differ
inpati
versu
outpati
outcom
suffici
number
subject
identifi
similar
trend
treatment
iv
antibiot
also
associ
reduct
airway
inflamm
specif
sputum
ne
measur
seen
cohort
although
decreas
ne
greater
iv
antibiot
treatment
log
compar
log
reduct
oral
antibiot
treatment
cohort
symptomat
improv
key
outcom
pex
treatment
patient
cf
interestingli
improv
pe
cfqr
correl
fev
improv
cohort
similarli
signific
correl
symptomat
improv
lung
function
recoveri
studi
pex
treat
iv
antibiot
suggest
patient
report
alon
insuffici
defin
resolut
exacerb
definit
resolut
also
includ
fev
recoveri
furthermor
larger
improv
fev
observ
goal
discharg
exacerb
treat
iv
antibiot
base
improv
lung
function
rather
symptomat
improv
limit
studi
includ
enrol
rel
small
number
subject
singl
center
offset
part
prospect
design
comprehens
collect
clinic
laboratori
data
concern
regard
select
bia
enrol
patient
live
closer
cf
center
abl
return
follow
week
characterist
cohort
gener
reflect
overal
clinic
popul
season
bia
less
like
enrol
occur
month
period
may
bia
airway
clearanc
treatment
frequenc
due
selfreport
addit
patient
cohort
milder
lung
diseas
preserv
lung
function
routin
expector
sputum
thu
find
may
generaliz
moder
sever
lung
diseas
viral
test
perform
expector
sputum
instead
nasal
wash
may
limit
detect
virus
howev
high
detect
rate
virus
one
third
sampl
suggest
virus
frequent
present
time
pex
treatment
school
age
children
cf
addit
viral
test
perform
visit
plausibl
subject
may
acquir
new
viru
week
visit
may
impact
measur
perform
studi
larger
cohort
stratifi
base
type
viru
could
clinic
meaning
could
perform
studi
due
small
number
subject
n
test
posit
viru
also
possibl
studi
underpow
sputum
bacteri
densiti
inflammatori
marker
studi
power
base
subject
howev
subject
match
sampl
evalu
primari
outcom
reduct
bacteri
densiti
may
affect
abil
detect
signific
chang
sputum
inflammatori
marker
given
variabl
measur
final
studi
limit
absenc
control
group
therefor
unclear
improv
seen
major
subject
relat
treatment
oral
antibiot
airway
clearanc
combin
studi
rais
import
question
relat
manag
pex
mainten
lung
function
remain
prioriti
care
pediatr
patient
cf
need
conclus
identifi
risk
factor
associ
failur
recov
baselin
lung
function
symptomat
improv
correl
lung
function
recoveri
closer
monitor
lung
function
consid
optim
pex
treatment
outpati
set
may
includ
standard
protocol
diagnosi
treatment
pex
home
monitor
exacerb
spirometri
visit
schedul
sooner
cf
clinic
visit
follow
exacerb
addit
better
understand
lung
function
affect
longitudin
need
especi
given
import
find
frequent
pex
associ
greater
rate
fev
declin
longitudin
assess
also
necessari
shortterm
clinic
improv
may
associ
long
term
outcom
includ
time
next
exacerb
treatment
pex
outpati
basi
oral
antibiot
like
increas
patient
cf
treat
cftr
modul
found
result
fewer
hospit
exacerb
cohort
schoolag
children
cf
found
treatment
twoweek
cours
oral
antibiot
associ
signific
improv
patient
report
outcom
lung
function
bacteri
densiti
sputum
inflammatori
marker
howev
studi
also
identifi
approxim
subject
fail
return
within
baselin
lung
function
remain
gap
understand
pex
treatment
mani
patient
fail
recov
baselin
lung
function
despit
symptomat
improv
futur
studi
need
optim
treatment
pex
outpati
set
oral
antibiot
data
serv
point
refer
expect
clinic
laboratori
respons
supplementari
data
articl
found
onlin
http
